Recently, Wang et al. (20) reported that MK2 inhibitor, MMI-0100, could ameliorate dextran sulfate sodium (DSS)-induced colitis in mice, suggesting that MK2 might be a therapeutic target for IBD. This evidence concerns the gene MAPKAPK2 and inflammatory bowel disease.